OTLKOutlook Therapeutics, Inc.

Nasdaq outlooktherapeutics.com


$ 7.66 $ -0.22 (-2.79 %)    

Friday, 10-May-2024 11:58:06 EDT
QQQ $ 441.66 $ -1.26 (-0.28 %)
DIA $ 394.61 $ -0.70 (-0.18 %)
SPY $ 520.39 $ -1.13 (-0.22 %)
TLT $ 90.12 $ -0.19 (-0.21 %)
GLD $ 218.75 $ -1.00 (-0.46 %)
$ 7.73
$ 7.88
$ 0.00 x 0
$ 7.68 x 200
$ 7.55 - $ 7.88
$ 4.00 - $ 40.60
223,914
na
100.59M
$ 1.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-14-2024 12-31-2023 10-Q
2 12-22-2023 09-30-2023 10-K
3 08-14-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 02-14-2023 12-31-2022 10-Q
6 12-29-2022 09-30-2022 10-K
7 08-10-2022 06-30-2022 10-Q
8 05-13-2022 03-31-2022 10-Q
9 02-14-2022 12-31-2021 10-Q
10 12-23-2021 09-30-2021 10-K
11 08-13-2021 06-30-2021 10-Q
12 05-14-2021 03-31-2021 10-Q
13 02-16-2021 12-31-2020 10-Q
14 12-23-2020 09-30-2020 10-K
15 08-14-2020 06-30-2020 10-Q
16 05-15-2020 03-31-2020 10-Q
17 02-14-2020 12-31-2019 10-Q
18 12-19-2019 09-30-2019 10-K
19 08-14-2019 06-30-2019 10-Q
20 05-15-2019 03-31-2019 10-Q
21 02-14-2019 12-31-2018 10-Q
22 12-18-2018 09-30-2018 10-K
23 08-14-2018 06-30-2018 10-Q
24 05-15-2018 03-31-2018 10-Q
25 02-14-2018 12-31-2017 10-Q
26 12-29-2017 09-30-2017 10-K
27 08-14-2017 06-30-2017 10-Q
28 05-15-2017 03-31-2017 10-Q
29 02-14-2017 12-31-2016 10-Q
30 12-29-2016 09-30-2016 10-K
31 08-15-2016 06-30-2016 10-Q
32 06-27-2016 03-31-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 outlook-therapeutics-files-prospectus-supplement-related-to-offer-sale-of-up-to-937m-of-common-stock-that-may-be-sold-under-sales-agreement

-SEC Filing

 insiders-buying-outlook-therapeutics-and-2-other-stocks

Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades.

 btig-upgrades-outlook-therapeutics-to-buy-announces-50-price-target

BTIG analyst Julian Harrison upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and announces $50 price target.

 hc-wainwright--co-maintains-buy-on-outlook-therapeutics-adjusts-price-target-to-30-reverse-stock-split-120

HC Wainwright & Co. analyst Douglas Tsao maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy, adjusts target to $30 ...

 gold-moves-lower-lululemon-shares-plummet

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 0.3% on Friday. The Dow traded do...

 why-cutera-shares-are-trading-lower-by-over-26-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected four...

 dow-dips-200-points-nike-shares-fall-after-q3-results

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 200 points. The Dow traded down 0....

 why-is-eye-disease-focused-outlook-therapeutics-stock-trading-higher-on-friday

Outlook Therapeutics stock sees uptick as European Medicines Agency committee issues positive opinion on ONS-5010/LYTENAVA for ...

Core News & Articles
Market-Moving News for March 22nd
03/22/2024 12:33:50

FDX: 13% | FedEx shares are trading higher after the company beat Q3 EPS expectations and authorized a new $5 billion share rep...

Core News & Articles

https://www.ema.europa.eu/en/medicines/human/EPAR/lytenava

 over-17m-bet-on-globalstar-check-out-these-4-penny-stocks-insiders-are-aggressively-buying

The Dow Jones index closed higher by around 47 points on Monday. When insiders purchase or sell shares, it indicates their conf...

 chardan-capital-upgrades-outlook-therapeutics-to-buy-announces-3-price-target

Chardan Capital analyst Daniil Gataulin upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and announces $3 pri...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION